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ABSTRACT
Carbapenem-resistant Acinetobacter baumannii
(CR-Ab) ranked third, with a frequency of 24.8%,
among 202 strains of multidrug-resistant bacteria
isolated from clinical samples in the main hospital
of New Caledonia in 2004. All CR-Ab isolates were
analysed by isoelectric focusing, conjugation,
pulsed-ﬁeld gel electrophoresis and PCR for the
presence of carbapenemase genes. Fifty CR-Ab
isolates produced carbapenemase OXA-23. The
isolates belonged to a single clone presenting
several subtypes, suggesting an endemic situation.
This study further illustrates the widespread
prevalence of carbapenemase OXA-23-producing
CR-Ab isolates in the South Paciﬁc.
Keywords Acinetobacter baumannii, carbapenemase,
hospital cohort, OXA-23
Original Submission: 8 March 2008; Revised Sub-
mission: 18 May 2008; Accepted: 3 June 2008
Edited by H. Seifert
Clin Microbiol Infect 2008; 14: 977–981
10.1111/j.1469-0691.2008.02068.x
Acinetobacter baumannii has emerged worldwide
as an important nosocomial pathogen, causing
outbreaks particularly in intensive care units, in
wards with patients who have serious underlying
illness, and in warm countries [1]. Imipenem is
among the drugs of choice for treatment of
nosocomial infections due to multidrug-resistant
(MDR) A. baumannii isolates. However, their efﬁ-
cacy is being increasingly compromised by the
emergence of carbapenem-hydrolysing b-lacta-
mases of molecular Ambler class B (VIM, IMP)
and class D (OXA-23, OXA-58) [1].
The aim of this study was to analyse the
molecular mechanisms of carbapenem resistance
in A. baumannii and to evaluate carbapenem-
resistant A. baumannii (CR-Ab) prevalence among
all MDR strains isolated at the central hospital of
Noumea (CHT), a 285-bed tertiary-referral centre.
Methicillin-resistant Staphylococcus aureus,
vancomycin-resistant Enterococcus and all Gram-
negative bacteria resistant to at least three agents
from distinct classes of antibiotics, including
extended-spectrum cephalosporin-resistant
Enterobacteriaceae, ceftazidime-resistant Pseudomo-
nas aeruginosa, CR-Ab, ceftazidime-resistant Burk-
holderia spp., and clavulanate–ticarcillin-resistant
Stenotrophomonas maltophilia, were considered to
be MDR. The study was conducted during the
entire year 2004 in the CHT. During that period,
15 320 patients were admitted. All MDR bacteria
included were from clinical samples. Colonization
and environmental samples were excluded. Only
the ﬁrst sample was analysed for patients who
had more than one MDR bacterial episode involv-
ing the same strain during the year of the study.
The incidence of MDR bacteria acquisition is
expressed as the number of MDR bacteria acqui-
sitions per 1000 patient-days in the hospital.
Standard bacteriological techniques and an
automated BacT ⁄Alert system (bioMe´rieux,
Marcy l’Etoile, France) were used to culture
bacteria. Bacterial isolates were initially identiﬁed
by various routine microbiological methods [2].
Identiﬁcation of A. baumannii isolates was con-
ﬁrmed by the detection and sequencing of the
intrinsic blaoxa-51-like gene [3]. Susceptibility of the
isolates to common antibacterial agents was
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tested using the disk diffusion method, according
to CLSI guidelines [4] and the British Society for
Antimicrobial Chemotherapy breakpoint for
colistin (http://www.bsac.org.uk). MICs of imip-
enem, meropenem, ceftriaxone, ceftazidime,
ampicillin–sulbactam, colistin, rifampicin and
tigecycline were determined with the Etest meth-
od using Mueller–Hinton agar (Oxoid) according
to the manufacturer’s recommendations.
Carbapenem-resistant and carbapenem-suscep-
tible A. baumannii isolates were typed by macro-
restriction analysis of ApaI-digested chromosomal
DNA separated by pulsed-ﬁeld gel electrophore-
sis (PFGE), using a CHEF-DR III apparatus
(Biorad) with pulses ranging from 5 to 35 s at a
voltage of 6 V ⁄ cm at 14C for 32 h. The criteria
used for PFGE pattern interpretation to deﬁne
epidemiological relatedness were as described by
Tenover et al. [5]. DNA extraction (genomic and
plasmid) and analysis, isoelectric focusing
and conjugation assays with rifampicin-resistant
A. baumannii strain CIP 7020 were performed as
described previously [6]. Genes coding for
Ambler class B and D carbapenemases were
sought by PCR using primers speciﬁc for blaIMP
[7], blaVIM [8], blaOXA-58 [9], blaOXA-23-like [9],
blaOXA-40-like [9] and blaOXA-51 ⁄ 69-like genes [3].
Similarly, the b-lactamase blaTEM and blaAMPC
genes, along with ISAbaI, which may be inserted
upstream of several b-lactamase genes, were
sought by PCR [10,11].
In total, 202 single clinical isolates of MDR
bacteria were collected during the study period,
representing a rate of 1.9 episodes per 1000
patient-days. The distribution of MDR bacteria
isolated is shown in Table 1. CR-Ab (24.8%)
ranked third behind expanded-spectrum cepha-
losporin-resistant Enterobacteriaceae (36.2%) and
methicillin-resistant S. aureus (34%). The inci-
dence rate of CR-Ab was 0.48 per 1000 patient-
days in hospital, with higher rates in the intensive
care unit (1.7) and in the respiratory ward (1.2).
All CR-Ab isolates were resistant to most agents
tested: all b-lactams (including imipenem and
meropenem), quinolones and aminoglycosides
(except for amikacin and tobramycin, which
remained active in 90% and 88%, respectively,
of the cases). All CR-Ab isolates were susceptible
to colistin. The MIC range in mg ⁄L was as
follows: 64 to >256 for ceftazidime, >256 for
ceftriaxone, >32 for imipenem and meropenem,
0.5–1 for colistin and rifampicin, 12–24 for ampi-
cillin–sulbactam, and 4 to >256 for tigecycline.
CR-Ab represented 64% of all A. baumannii iso-
lates obtained during the entire year 2004 (50 ⁄ 78
strains, data not shown).
Carbapenem-resistant and carbapenem-suscep-
tible A. baumannii isolates were subjected to PFGE
(Fig. 1). Imipenem-susceptible isolates displayed
signiﬁcant variability, and none appeared to be
genetically related to carbapenem-resistant iso-
lates, which clustered into a single PFGE type
represented by two subtypes, A1 and A2. CR-Ab
isolates were found in different wards, across all
ethnic and age groups (data not shown), and were
seen throughout 2004 at the CHT; moreover, the
number of isolates did not follow a clear epidemic
curve. The PFGE proﬁle of CR-Ab strains differed
from those of the reference strains expressing
extended-spectrum b-lactamases, e.g. VEB-1 and
PER-1, and from those of strains expressing
carbapenem-hydrolysing oxacillinases, e.g. OXA-
40 and OXA-58; however, the proﬁles were
very similar to those of the French Polynesian
A. baumannii OXA-23 Tah-1 clone [12].
The A. baumannii isolates tested positive by
PCR for the acquired blaOXA-23-like and blaTEM-
like genes, and for the naturally occurring blaOXA-51-
like and blaAMPC-like genes. Sequencing of the
ampliﬁed fragments conﬁrmed the presence of
blaOXA-23, blaOXA-51, blaTEM-1 and blaAMPC genes,
identical to those identiﬁed in A. baumannii OXA-
23 Tah-1 [12]. PCR analysis revealed that blaOXA-23
was not embedded in a class 1 integron, but was
surrounded by ISAbaI sequences in a manner
similar to that of the prototype blaOXA-23 gene, as
described by Corvec et al. [10]. Isoelectric focusing
analysis conﬁrmed that, in addition to OXA-23
(pI 6.9), the chromosomal class C b-lactamase
(pI >9.0) and TEM-1 penicillinase (pI 5.4) were also
expressed (data not shown). Plasmid analysis
Table 1. Multidrug-resistant (MDR) bacteria isolated in
2004
No. of
isolates
(%)a
Incidence
per 1000
patient-days
Expanded-spectrum cephalosporin-resistant
Enterobacteriaceae
73 (36.2) 0.7
Methicillin-resistant Staphylococcus aureus 68 (33.5) 0.6
Imipenem-resistant Acinetobacter baumannii 50 (24.8) 0.48
Ceftazidime-resistant Pseudomonas aeruginosa 7 (3.5) 0.07
Ticarcillin–clavulanate-resistant
Stenotrophomonas maltophilia
4 (2) 0.04
Vancomycin-resistant Enterococcus spp. 0 0
All MDR bacteria 202 1.9
aPercentage of total isolates.
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Fig. 1. Pulsed-ﬁeld gel electrophoresis (PFGE) patterns of Acinetobacter baumannii isolates. The assigned numbers of
A. baumannii isolates are shown on the left of the ﬁgure. The positions of molecular size markers in kilobases (standard) are
shown under the last gel. Associated data with pulsotypes are shown on the right side of the gel. Lanes 41, 42, 46 and 47
correspond to reference strains supplied by Hoˆpital de Biceˆtre, Paris, France: Ab Per-1 [17], Ab Oxa-58 [18], Ab Veb-1
and Ab Veb-1 AYE [2,19], respectively. Lane 28 corresponds to the A. baumannii strain carrying OXA-23 carbapenemase,
which was isolated in Tahiti, French Polynesia, in 2004 [12]. Cluster analysis was performed by the unweighted pair group
method with arithmetic averages (UPGMA), and the percentage relatedness was calculated using the band-based Dice
coefﬁcient with a tolerance setting of 1.5% band tolerance and 1.5% optimization. Only bands above 48 kb were
considered for analysis. Isolates corresponding to an 87% clustering threshold were considered to belong to the PFGE
pattern [20]. Gel images were analysed with BioNumerics version 4.5 software (Applied Maths, Kortrijk, Belgium).
Research Notes 979
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 970–981
revealed a 60-kb plasmid, albeit inconsistently. If
detected, it was transferred to rifampicin-resistant
A. baumannii CIP 7020 (at a low frequency of
transfer, 10)7). This plasmid carries only the
blaOXA-23 gene, OXA-23, without additional antibi-
otic resistance markers.
Outbreaks of OXA-23-producing A. baumannii
isolates have been reported repeatedly in Europe,
South America and Asia [12–16]. This study
identiﬁed an OXA-23-positive A. baumannii clone
with an alarmingly high frequency among all
MDR bacteria in 2004. The frequency of isolation
of CR-Ab in this study was as high as that of
methicillin-resistant S. aureus and expanded-spec-
trum cephalosporin-resistant Enterobacteriaceae;
this is unusual and worrying, as a prevalence of
<1% has been described by the national French
network (the Nosocomial Infection Alert, Investi-
gation and Surveillance Network, http://
www.invs.sante.fr/surveillance/raisin). CR-Ab
isolation varies widely in different countries [13]
and has been mostly sporadic. Interestingly, in
New Caledonia, a retrospective analysis of our
bacteriology database of antibiotic resistance sus-
ceptibility patterns revealed that this CR-Ab strain
might have been present in the hospital since at
least December 2001, and has now spread to all
wards of the hospital. The recently described
AbOXA-23 strain Tah-1, responsible for an out-
break in French Polynesia [12], showed 100%
identity in PFGE patterns and resistance gene
characterization with some New Caledonian iso-
lates. Tahiti, an island also located in the Paciﬁc
Ocean, but separated from New Caledonia by
about 6000 km, illustrates the extent of the geo-
graphical distribution of this carbapenemase gene
in the South Paciﬁc region. Moreover, clinical
strains isolated in 2005 in Westmead Hospital,
Sydney (Australia), with an identical antibiotic
susceptibility proﬁle, displayed a similar PFGE
pattern and expressed OXA-23 in a manner
similar to the endemic CR-Ab strain (S. Le Hello,
personal communication).
In conclusion, in New Caledonia, OXA-
23-producing A. baumannii isolates represent an
endemic lineage, which is present in neighbour-
ing countries in the Paciﬁc. These ﬁndings
highlight the importance of being aware of local
speciﬁcities in MDR bacterial ecology and
resistance levels for initiating proper antimicro-
bial empirical therapy and for implementing
effective infection control policies in a general
hospital.
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